Doris Hansen, MD, discusses the efficacy of daratumumab, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone in newly diagnosed myeloma.
Doris Hansen, MD
Doris Hansen, MD, is an assistant member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy.
Articles by Doris Hansen, MD